Department of Gastroenterology and Endoscopy, National Cancer Center Hospital East, Kashiwa, Japan.
Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN.
Photochem Photobiol. 2020 May;96(3):517-523. doi: 10.1111/php.13206. Epub 2020 Mar 17.
The clinical application of photodynamic therapy (PDT) for gastrointestinal (GI) neoplastic lesions has been developed with appreciation for the great efforts and kind support of Dr. Tom Dougherty and his followers' contributions. There are several published studies on clinical PDT in the field of GI oncology. Esophageal cancer was one of the first clinical indications for PDT that was approved as an endoscopic procedure in both the United States and Japan. PDT was initially used as a palliative local treatment for patients with obstructive esophageal cancer. PDT is also indicated for eradicative therapy for dysplastic Barret's esophagus, which is the precursor state of esophageal adenocarcinoma, with the support of level one evidence. In Japan, PDT was approved as a curative treatment for superficial esophageal carcinoma lesions, which are difficult to treat with endoscopic resection. Further, PDT using second-generation photosensitizers is approved for early local failure after radiotherapy, for which treatment with other modalities is difficult. PDT has also been assessed in other GI cancers, including gastric cancer, biliary cancer and pancreatic cancer. In this review, we overview the history and state of PDT for GI cancer.
光动力疗法（PDT）在胃肠道（GI）肿瘤病变中的临床应用，得益于 Tom Dougherty 博士及其追随者的不懈努力和大力支持。在 GI 肿瘤学领域，有许多关于临床 PDT 的已发表研究。食管癌是 PDT 的首批临床适应证之一，在美国和日本均被批准为内镜治疗方法。PDT 最初被用作治疗梗阻性食管癌患者的姑息性局部治疗方法。PDT 也被用于消除 Barrett 食管异型增生，这是食管腺癌的前期状态，有一级证据支持。在日本，PDT 被批准用于治疗难以通过内镜切除的表浅性食管癌病变。此外，第二代光敏剂的 PDT 也被批准用于放疗后早期局部复发的治疗，对于这种情况，其他治疗方法较为困难。PDT 也已在其他胃肠道癌症中进行了评估，包括胃癌、胆管癌和胰腺癌。在这篇综述中，我们概述了 PDT 治疗胃肠道癌症的历史和现状。
